- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Português (Portugal)
- Polski
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Scholar Rock Holding Corp (SRRK)
Scholar Rock Holding Corp stock price live, this page displays NASDAQ SRRK stock exchange data. View the SRRK premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Scholar Rock Holding Corp real time stock price chart below.
What Is the Scholar Rock Holding Corp Stock Price Today?
The Scholar Rock Holding Corp stock price today is 31.96.
What Is the Stock Symbol for Scholar Rock Holding Corp?
The stock symbol for Scholar Rock Holding Corp is ""SRRK.""
What Stock Exchange Does Scholar Rock Holding Corp Trade On?
Scholar Rock Holding Corp is listed and trades on the NASDAQ stock exchange.
Is Scholar Rock Holding Corp a Good Stock to Buy?
Determining whether Scholar Rock Holding Corp—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the SRRK quote. (ISIN: US80706P1030)
What Is the Scholar Rock Holding Corp Stock Price Today?
The Scholar Rock Holding Corp stock price today is 31.96.
What Is the Stock Symbol for Scholar Rock Holding Corp?
The stock symbol for Scholar Rock Holding Corp is ""SRRK.""
What Stock Exchange Does Scholar Rock Holding Corp Trade On?
Scholar Rock Holding Corp is listed and trades on the NASDAQ stock exchange.
Is Scholar Rock Holding Corp a Good Stock to Buy?
Determining whether Scholar Rock Holding Corp—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the SRRK quote. (ISIN: US80706P1030)
31.96
+0.56(+1.78%)
Closed·
After Hours
32.79+0.84(+2.61%)
·
Fair Value
An estimate of a Scholar Rock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
31.19
32.66
52 wk Range
6.76
46.98
SRRK Scorecard
Full Analysis
4 analysts have revised their earnings downwards for the upcoming period
SRRK is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a Scholar Rock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
31.1932.66
52 wk Range
6.7646.98
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
SRRK Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a Scholar Rock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Analysts Sentiment
Strong Buy
Price Target
50.00
Upside
+56.45%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Stock has taken a big hit over the last week
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell
Scholar Rock Holding Corp Company Profile
Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. Its transforming growth factor beta (TGFß) superfamily biology, its novel understanding of the molecular mechanisms of growth factor activation enabled us to develop a proprietary platform for development of monoclonal antibodies that locally and selectively target the precursor. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is developing a pipeline of product candidates to deliver novel therapies to treat a range of serious diseases, including neuromuscular disorders, cardiometabolic disorders, cancer, fibrosis, and iron-restricted anemia. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.
Scholar Rock Holding Corp SWOT Analysis
Pivotal Trial Awaits | Scholar Rock's SAPPHIRE trial for apitegromab in SMA nears completion, with potential to revolutionize treatment and drive significant market valuation |
Oncology Breakthrough | SRK-181 shows promise in overcoming resistance to immune checkpoint inhibitors, addressing a critical challenge in cancer treatment |
Expanding Horizons | Scholar Rock ventures into the lucrative obesity market with EMBRAZE trial and SRK-439, diversifying its pipeline beyond core focus areas |
Financial Outlook | Analyst targets range from $29 to $31, with potential for significant upside if pivotal trials succeed, despite current lack of revenue-generating assets |
Scholar Rock Holding Corp Earnings Call Summary for Q2/2025
- Scholar Rock reports Q2 2025 EPS of -0.98, missing estimates by 48.48%, leading to a 14.44% stock drop in premarket trading
- Company maintains strong liquidity with $295 million cash reserves and a current ratio of 10.25, despite being unprofitable
- FDA approval for epitigramab anticipated in September 2025, with positive Phase II results for Spinal Muscular Atrophy treatment
- CEO David Hillal emphasizes urgency in SMA treatment and scaling for growth as a commercial stage biopharmaceutical company
- Risks include continued financial underperformance, regulatory hurdles, and market competition in the SMA treatment space
Last Updated: 06/08/2025, 14:30
Read Full TranscriptCompare SRRK to Peers and Sector
Metrics to compare | SRRK | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipSRRKPeersSector | |
|---|---|---|---|---|
P/E Ratio | −9.7x | −3.1x | −0.5x | |
PEG Ratio | 0.34 | 0.00 | 0.00 | |
Price/Book | 13.2x | 2.7x | 2.6x | |
Price / LTM Sales | - | 150.6x | 3.3x | |
Upside (Analyst Target) | 56.4% | 196.4% | 43.4% | |
Fair Value Upside | Unlock | 5.5% | 7.1% | Unlock |
Analyst Ratings
10 Buy
0 Hold
0 Sell
Ratings:
10 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 50.00
(+56.45% Upside)
Earnings
Latest Release
Aug 06, 2025
EPS / Forecast
-0.98 / -0.66
Revenue / Forecast
-- / --
People Also Watch
FAQ
What Stock Exchange Does Scholar Rock Trade On?
Scholar Rock is listed and trades on the Nasdaq Stock Exchange stock exchange.
What Is the Stock Symbol for Scholar Rock?
The stock symbol for Scholar Rock is "SRRK."
What Is the Scholar Rock Market Cap?
As of today, Scholar Rock market cap is 3.07B.
What Is Scholar Rock's Earnings Per Share (TTM)?
The Scholar Rock EPS (TTM) is -3.29.
When Is the Next Scholar Rock Earnings Date?
Scholar Rock will release its next earnings report on 16 Nov 2025.
From a Technical Analysis Perspective, Is SRRK a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
How Many Times Has Scholar Rock Stock Split?
Scholar Rock has split 0 times.
How Many Employees Does Scholar Rock Have?
Scholar Rock has 128 employees.
What is the current trading status of Scholar Rock (SRRK)?
As of 10 Aug 2025, Scholar Rock (SRRK) is trading at a price of 31.96, with a previous close of 31.40. The stock has fluctuated within a day range of 31.19 to 32.66, while its 52-week range spans from 6.76 to 46.98.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.